Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial

Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.

Regulatory & Clinical Milestone

Drug Profile & Mechanism

Clinical Advantages:

• Improved iron use efficiency vs. traditional ESAs
• Avoidance of intravenous injections (patient convenience)
• Favorable safety profile (reduced cardiovascular risk vs. ESAs)
• Potential to overcome hyporesponsiveness seen in current therapies

Financial Terms

Strategic Context

Pipeline & Platform Outlook

• Insilico Portfolio: 30+ AI-discovered programs across fibrosis, oncology, immunology; ISM4808 first CKD asset to reach clinic
• Platform Expansion: Chemistry42 now deployed for multiple pharma partnerships; milestone achievement demonstrates commercial viability
• TaiGen Strategy: Builds anemia franchise alongside existing portfolio; Greater China commercial infrastructure leveraged

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, milestone achievements, and commercial potential for ISM4808. Actual results may differ due to trial outcomes, regulatory requirements, and competitive dynamics in the CKD anemia market.-Fineline Info & Tech